Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Lenabasum for diffuse cutaneous systemic sclerosis aces phase II trial

22 May 2020

Treatment with lenabasum is safe and helps improve outcomes in patients with diffuse cutaneous systemic sclerosis (dcSSc), according to the results of a phase II study.

The study randomized adult patients with dcSSc for ≤6 years and on stable standard‐of‐care treatment to receive either lenabasum (n=27) or placebo (n=15). The study drug was given at 5 mg once daily (QD), 20 mg QD or 20 mg twice daily (BID) for 4 weeks, then 20 mg BID for 8 weeks. Researchers conducted safety and efficacy assessments at weeks 4, 8, 12 and 16.

Active treatment led to a more favourable improvement in American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, which reached 0.33 vs 0.00 with placebo at week 16 (p=0.07). Lenabasum also produced greater improvements in other efficacy outcomes that assessed overall disease, skin involvement and patient‐reported function.

Gene expression in inflammation and fibrosis pathways decreased more with the study drug vs placebo, with significant improvements in inflammation and fibrosis by histological evaluation of skin biopsies (p≤0.05).

Adverse events (AEs) occurred in 63 percent of patients in the lenabasum group and in 60 percent of the placebo group. Commonly reported AEs were dizziness (22 percent vs 13 percent), fatigue (19 percent vs 7 percent), headache (11 percent vs 7 percent), arthralgia (11 percent vs 7 percent), upper respiratory tract infection (11 percent vs 0 percent), nausea (4 percent vs 13 percent) and decreased forced vital capacity (0 percent vs 13 percent). There were no serious AEs related to active treatment.

Despite a short trial duration and a small number of patients, the findings are encouraging and support the therapeutic potential of lenabasum in dcSSc, the researchers said, adding that further evaluation of the drug is warranted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.